A Phase I clinical study conducted by Novavax has demonstrated positive top-line results of its respiratory syncytial virus (RSV) fusion (F) recombinant nanoparticle vaccine candidate.

The blinded placebo-controlled dose-escalating Phase I trial enrolled 150 healthy adults, aged from 18 to 49 years old, who were allocated to six cohorts that included 4 dose levels of vaccine.

The study is intended to assess the safety and tolerability of aluminum phosphate-adjuvanted (adjuvant) and unadjuvanted formulations of its RSV vaccine candidate, while evaluating total and neutralising anti-RSV antibody responses and the impact of the adjuvant.

Novavax RSV vaccine candidate demonstrated high antibody response, a significant dose-response pattern, high rates of seroconversion at all doses including a rate of 100% at the highest-dose-adjuvant group, and a higher plaque reduction neutralising titers in all the vaccine groups containing adjuvant.

Novavax president and CEO Stanley Erck said the clinical data provides a pathway to move forward in studying the vaccine candidate in infants, young children and older adults affected by RSV.

Novavax senior vice president and chief medical officer Gregory Glenn said the findings from the Phase I trial are consistent with the preclinical results in relevant animal models, which indicated the vaccine candidate was well-tolerated, highly immunogenic and produced functional antibodies that neutralised RSV.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.